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Excitotoxic mechanisms in non-motor dysfunctions and levodopa-induced 
dyskinesia in Parkinson's disease: the role of the interaction between the 
dopaminergic and the kynurenine system 
 
Abstract:  Parkinson’s disease is a common progressing neurodegenerative disorder 
presenting with characteristic motor symptoms. Non-motor dysfunctions and therapy-related 
complications frequently develop, but are often underdiagnosed and undertreated. Levodopa-
induced dyskinesia and impulse control disorders are suggested to share pathophysiological 
processes and be related to alterations of the glutamatergic neurotransmission. Anti-
glutamatergic interventions are therefore worth considering: several lines of evidence already 
indicate their beneficial effect. The kynurenine pathway offers the endogenous glutamate 
receptor antagonist kynurenic acid, which may provide a promising candidate for future drug 
development with the aim of assessment of the motor symptoms and therapy-related 
complications of Parkinson’s disease. 
 
Keywords: Parkinson’s disease, kynurenic acid, neuroprotection, NMDA receptor, glutamate, 
levodopa-induced dyskinesia, excitotoxicity 
 
 
Introduction 
 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder presenting with 
characteristic motor symptoms: rigidity, resting tremor, bradykinesia and postural instability 
1
. 
Epidemiological data indicate that the overall prevalence of PD is around 1.5% with no 
gender differences; the prevalence increases with the age 
2, 3
. The neuropathological 
background of PD is the progressive selective degeneration of dopaminergic neurons in the 
substantia nigra 
4
. However, as our understanding of the pathophysiological process of PD has 
improved, it has become evident that, besides the dopaminergic system, the cholinergic, 
serotoninergic, noradrenergic and glutamatergic systems are also affected. Glutamate is the 
main excitatory neurotransmitter in the human brain, but the excessive stimulation of 
glutamatergic receptors may lead to neuronal damage, a process known as excitotoxicity. 
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Excitotoxicity has been implicated in the pathological mechanisms of several 
neurodegenerative disorders, including PD 
5, 6
. 
The pathomechanism of PD has still not yet been fully clarified despite extensive 
research, but genetic and environmental factors have both been suggested to contribute. 
Most PD cases are sporadic, but a minority of the patients have a clear familial disease.  
The role of hereditary factors has been strengthened by epidemiological studies 
indicating a significantly higher risk of developing the disease among first-degree 
relatives of PD patients 
7-9
. Genetic investigations in families with inherited forms of PD 
have identified several gene mutations; these data also promoted the understanding of 
the pathogenesis of the disorder 
10, 11
.  Later, studies suggested that genetic factors may 
contribute to a higher risk of PD in the general population as well, and environmental 
factors combined with a genetic predisposition may result together in the development 
of PD 
12
.  
The gold standard of PD therapy currently remains dopamine (DA) replacement with oral 
levodopa, which offers good symptomatic relief for the motor symptoms, but can be 
associated with therapy-related complications such as levodopa-induced dyskinesia (LID) or 
impulse control disorders (ICDs). Non-motor symptoms (NMs) of PD are often unrecognized 
and undertreated, although they may have a serious impact on the quality of life.  They often 
precede the development of motor symptoms and their frequency increases in parallel with the 
progression of PD 
13, 14
. NMs can be classified into four main groups: autonomic symptoms, 
sensory symptoms, sleep disorders and neuropsychiatric symptoms (Table 1. ).  
 
Table 1. Non-motor  dysfunctions in Parkinson’s disease 
Autonomic symptoms orthostatic hypotension 
gastrointestinal dysfunctions 
nausea and vomiting 
sexual dysfunctions 
bladder dysfunction 
Sensory disturbances anosmia 
paraesthesias 
pain  
taste deficits 
Sleep disorders rapid eye movement disorder 
restless leg syndrome 
excessive daytime sleepiness 
vivid dreaming  
insomnia 
Neuropsychiatric disorders psychosis 
depression 
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cognitive impairment or dementia 
anxiety  
dysphoria 
impulse control disorders 
 
 
ICDs include pathological gambling, hypersexuality, compulsive shopping and binge eating. 
Gambling and hypersexuality show a male predominance, while compulsive shopping and 
eating are more frequent among female PD patients
15, 16
. The development of ICDs is 
associated with the use of DA agonists
17
. ICDs are common complications of PD, although 
they are often underdiagnosed. Epidemiological data indicate the prevalence of ICDs as being 
between 6 and 18% of PD patients
16, 18, 19
. There are several risk factors which have been 
associated with the development of ICDs: a younger age, DA agonists or a higher levodopa 
dosage, a family history of gambling or alcohol problems, impulsivity and depression
20
. The 
exact pathological mechanisms of ICDs are not yet fully clarified. 
 
 
The role of interactions of the dopaminergic and glutamatergic systems in the 
development of therapy-related complications of PD 
 
It has recently been suggested that the pathophysiological background of LID and ICDs is 
common, and involves alterations of the glutamatergic neurotransmission
20-22
. Presynaptic 
changes affecting DA release and postsynaptic changes affecting DA receptors have been 
described in LID, and are hypothesized to contribute to the development of ICDs too. DA 
exerts its effect mainly on the medium spiny neurons of the caudate and putamen, which are 
rich in glutamate receptors. Interactions of DA and glutamate receptors play an important role 
in the normal function of the basal ganglia, and this fine balance is disrupted in PD 
23-25
. DA 
replacement therapy results in a chronic intermittent, non-physiological stimulation of DA 
receptors instead of the physiological tonic stimulation, which leads to changes in the 
glutamate receptors on the striatal spiny neurons. Experimental data from both animal models 
and humans indicate that the phosphorylation of glutamate receptors undergoes a change. 
Phosphorylation of the NMDA receptors is an important mechanism in the regulation of 
NMDA receptor function. Several kinases have been identified which are able to 
phosphorylate ionotropic glutamate receptors, including protein kinase A, protein 
kinase C, Ca(2+)/calmodulin-dependent protein kinase II, Src/Fyn non-receptor tyrosine 
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kinases, and cyclin dependent kinase-5 
26
. In PD, different signal transduction cascades - 
the cyclic adenosine monophosphate  (cAMP)-protein  kinase  A-mediated and the calcium-
calmodulin-dependent  kinase  II  pathways - are activated,  consequently the subunit 
composition changes and NMDA receptors become phosphorylated 
27, 28
. Serin 
phosphorylation of the NR1 subunit and tyrosine phosphorylation of the NR2 subunit of 
the NMDA receptors have been described after long-term dopaminergic treatment 
29
. 
The hyperphosphorylation of the NMDA receptors leads to long-term potentiation of their 
sensitivity 
30
 (Fig.1.). Another important kinase involved in the phosphorylation of 
NMDA receptors and the mediation of dopamine-dependent signaling processes is 
glycogen synthase kinase 3-beta (GSK3β). Activation of GSK3β has been proved to 
inhibit presynaptic glutamate release, alter the expression of NMDA receptors and 
under hyperdopaminergic conditions, affect synaptic NMDA-mediated currents
31-33
. 
GSK3 β has been described to be involved in several pathogenic processes of PD, 
including oxidative stress, protein aggregation and neuroinflammation
34
.  
 
 
 
 
These alterations result in hypersensitivity towards DA and the development of motor 
fluctuations. The possible role of the connection of DA and glutamate receptors in the 
pathogenesis of ICDs has been strengthened by a genetic study which found an association of 
the GRIN2B gene with ICDs 
35
. GRIN2B is responsible for the synthesis of the NR2B subunit 
of NMDA receptors, which is the predominant form of the striatal NMDA receptors.  
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The kynurenine pathway and its interaction with the dopaminergic system 
The kynurenine pathway (KP) is the main route of the tryptophan (Trp) metabolism, 
responsible for more than 95% of Trp degradation (Fig. 2.) 
36, 37
. It has been recognized 
already in the 1980s that the enzymatic cascade of the KP generates several neuroactive 
compounds
38, 39
. The first, rate-limiting step of the KP is the enzymatic degradation of Trp, 
this step catalyzed by indoleamine-2,3-dioxygenase (IDO). The KP divides into two main 
branches at a central intermediate, L-kynurenine (KYN). The first arm of the pathway is the 
conversion of KYN into kynurenic acid (KYNA). KYNA synthesis can be attributed to the 
action of kynurenine-aminotransferases (KATs), so far 4 subtypes of this enzyme are known, 
which have slightly different biochemical profile 
40
.  
The other branch of the KP begins with the conversion osf KYN by kynurenine-3-
monooxygenase (KMO) into 3-hydroxy-kynurenine. This is further metabolized by multiple 
enzymatic steps, gives rise to the neurotoxic quinolinic acid (QUIN) and finally ends at the 
production of the essential coenzyme nicotinamide adenine dinucleotide (NAD).  
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KYNA is a broad-spectrum endogenous inhibitor of ionotropic excitatory amino acid 
receptors. It has the highest affinity for the N-methyl-D-aspartate (NMDA) type glutamate 
receptors, exerting its effect mainly by binding to the strychnine-insensitive glycine-binding 
site, but at a higher concentration it can also bind to the glutamate-binding site 
41, 42
. On 
another type of glutamate receptors, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors, KYNA exerts a concentration-dependent dual effect: in a higher, 
micromolar concentration it is an inhibitor, while in a nanomolar concentration it acts as a 
facilitator 
43, 44
. KYNA has also been described to be a non-competitive inhibitor of the 
presynaptic α7 nicotinic acetylcholine receptors thereby reducing presynaptic glutamate 
release 
45, 46
. Later investigations could not confirm this inhibitory potential 
47
. However, 
KAT-deletion and consequently a loss of KYNA resulted in an increased sensitivity of α7 
nicotinic acetylcholine receptors, suggesting a regulatory role of KYNA on them
48
. 
Currently, the possible role of KYNA on α7 nicotinic acetylcholine receptors is not 
clearly understood and further research is needed to describe any potential effect 
49
. 
It was subsequently confirmed that KYNA is an agonist of the previously orphan G-protein 
coupled receptor GPR35, which has also been suggested to contribute to the reduction of 
extracellular glutamate in the brain 
50, 51
. The complex modes of actions suggest that KYNA 
has an important neuromodulatory role in the central nervous system and it is involved in the 
regulation of glutamatergic and cholinergic neurotransmission (Table 2. ).  
 
Table 2. Receptor targets of KYNA and its effects on them 
NMDA receptors antagonist 
AMPA receptors facilitation in nanomolar, inhibition in micromolar  concentration 
α7-nicotinic acetylcholine receptors antagonist 
GPR35 receptor agonist 
 
 
Increasing evidence confirms the neuroprotective capacity of KYNA in different conditions, 
such as QUIN, NMDA and glutamate-induced toxicity or ischaemia 
52-55
. On the other hand, 
QUIN is a neurotoxic compound which exerts its deteriorating effect mainly via NMDA 
agonism, but also contributes to the generation of free radicals, promotes lipid peroxidation 
and decreases antioxidant capacity
56-60
. Interestingly, in contrast with KYNA, QUIN enhances 
glutamate release 
61
.  
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An important aspect regarding the effects of KYNA is its close connection with the 
dopaminergic system. Elevations of KYNA levels result in the inhibition of dopamine release. 
This effect is suggested to be mediated predominantly by the α7-nicotinic acetylcholine 
receptors, but at higher concentrations this effect may be due to the inhibition of glutamate 
receptors 
62, 63
. Conversely, levodopa substitution has also been confirmed to reduce KYNA 
levels 
64
. (Fig. 3.)  
 
 
These results further strengthen the concept that KYNA has an important role in the 
regulation of glutamatergic, cholinergic and dopaminergic neurotransmission, which may also 
have important implications for the pathophysiology of PD. Alterations of KYNA are able to 
modulate DA levels, while reduced KYNA levels may also increase vulnerability towards 
excitotoxic effects by enhancing glutamatergic influences.
65
 Alterations in the delicate 
balance of neuroactive kynurenines have been confirmed in several neurodegenerative 
diseases, including Alzheimer’s disease, multiple sclerosis and Huntington’s disease 
66-69
. KP 
changes have also been described in PD. Kynurenine/Trp ratios were increased, while serum 
Trp levels were decreased in PD patients as compared with healthy controls 
70
. Ogawa et al. 
have measured reduced concentrations of KYN and KYNA in several brain regions of PD 
patients, including the frontal cortex, putamen and substantia nigra 
71
. They also confirmed a 
significantly increased 3-OH-KYN levels in the putamen and substantia nigra of PD brains; 
this compound may contribute to the oxidative stress and consequently to the neuronal 
damage 
71
. KP alterations have also been measured at the periphery: in the plasma of PD 
patients, the KYNA level and the KAT activity have been found to be decreased 
72
. 
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Therapeutic opportunities by glutamate antagonism 
 
Memantine, a weak NMDA antagonist, has been revealed to have beneficial symptomatic 
effects for dementia associated with PD and, interestingly, it may additionally improve motor 
symptoms 
73-76
. Case reports suggested that memantine may also improve LID 
77, 78
. So far 
there is no data concerning its therapeutic effect on non-motor symptoms or ICDs.  
Another anti-glutamatergic agent, amantadine has been confirmed to improve LID symptoms 
both as acute and as chronic therapy 
79-81
. It was proved that the beneficial effect of 
amantadine is long-lasting, and is sustained even after 1 year of continuous therapy 
82
. The 
beneficial effect of amantadine on LID is suggested to be modulated at least in part by 
NMDA inhibition 
83
. Amantadine has been already tested for the therapeutic management of 
ICDs with promising results. A small study has revealed that amantadine is capable of 
reducing pathological gambling in PD patients 
6
. The effect of amantadine was recently 
confirmed by another small-scale study, which described the behavioral background of this 
effect 
84
. The possible therapeutic effect of amantadine was strengthened by other studies 
involving patients with pathological gambling without PD 
85
. Case reports have described the 
beneficial effect of amantadine on punding as well, which is another complication of 
dopamine-replacement therapy 
86, 87
. 
These results suggest that anti-glutamatergic therapies may be valuable options for the 
management of not only the motor symptoms, but also of the therapy-related complications of 
PD. KYNA is the only known endogenous NMDA antagonist, which has been suggested to 
provide symptomatic treatment and also neuroprotection 
88, 89
. In an experimental PD model, 
KYNA was able to alleviate parkinsonian motor symptoms 
89
. There is growing evidence 
indicating that the hypersensitivity of NMDA receptors plays an important role in the 
development of LID and other complications of PD, and the NMDA antagonist KYNA may 
therefore be beneficial for the treatment of these complications too. Elevation of the brain 
KYNA levels has been already examined in experimental PD models. KYNA itself can cross 
the blood-brain barrier poorly, but the peripheral administration of its precursor, KYN, 
together with the organic acid transport inhibitor probenecid, results in significant brain 
KYNA content elevations. This treatment proved to be neuroprotective in a 6-
hydroxydopamine model of PD 
88
. Another possibility is the synthesis of kynurenine 
derivatives, in another animal model of PD, the neuroprotective effects of several synthetic 
kynurenines were confirmed 
90
. Another option to achieve a KYNA elevation would be to 
influence the enzymatic machinery of the KP; accordingly, KMO inhibition results in a shift 
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towards the production of KYNA. This method resulted in the improvement of LID, while the 
antiparkinsonian effect of levodopa was not diminished 
91, 92
. 
There are not yet data regarding the effects of KYNA on the non-motor complications of PD, 
but the promising results with amantadine, and the fact that KYNA is able to improve LID, 
suggest that KYNA may be of therapeutic value for these conditions too. Further 
investigations are worth considering to assess the potential therapeutic benefits of KYNA in 
PD. From this aspect it is of interest to produce synthethic KNYA derivatives which may 
have more favourable pharmacokinetic properties than those of KYNA, such as an improved 
receptor selectivity or an improved blood-brain barrier penetration. Several synthethic KYNA 
analogues have already been developed to achieve neuroprotection 
93
. 
 
Syntheses of kynurenic acid derivatives 
The general procedure for the synthesis of 4-hydroxyquinolinic acid can be achieved by a 
modified Conrad-Limpach method starting from the commercially available substituted aryl 
amines 1 
93, 94
. The first step involves enamine bond formation by using dimethyl 
acetylenedicarboxylate or diethyl acetylenedicarboxylate  resulting in 2 (Scheme 1). 
 
Scheme 1.  
The intermediate fumarate 2 is then cyclized at high temperature, yielding 4-hydroxy-2-
carboxylates 3 respectively. For 3 the enol-oxo tautomerism is possible. This equilibrium is 
shifted to the oxo form when C-2 contains an ester function, while the presence of a 
carboxylic group at C-2 indicate the enol form (Scheme 1). For the transformations of the 4-
hydroxy-quinoline derivatives, the free acids (KYNA derivatives) are needed. The hydrolysis 
of the esters is generally performed in methanolic alkali media, followed by acidification with 
HCl, resulting in kynurenic acid derivatives 4 (Scheme 1). 
The transformations of KYNA derivatives can be achieved in different ways: by the 
transformation of the synthetically active hydroxy group at position 4 or by the conversion of 
the carboxylic function at position 2 
93
. 
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The aim in the last few years has been to introduce a cationic centre in the side-chain so as to 
have good water solubility and better penetration ability of the products trough the blood- 
brain barrier 
94
. 
The coupling between KYNA and 2-dimethylaminoethylamine was first achieved by using 
N,N’-diisopropylcarbodiimide in the presence of 1-hydroxybenzotriazole hydrate,  yielding 5 
(Scheme 2). 
  
 
Scheme 2.  
 
The excellent biological activity of 5 led us to prepare a number of analogues 
93, 94
. Several of 
them is shown in Scheme 2. For example, by using 2-diethylaminoethylamine as starting 
amine, 6 was synthesized as a diethyl analogue of 2 (Scheme 2), and analogues 7, 8 and 9, 
containing the tertiary nitrogen in different ring systems, were prepared by reacting KYNA 
with 2-pyrrolidinoethylamine, 2-piperidinoethylamine and 2-morpholinoethylamine, 
respectively. 
The synthethic KYNA analogues have already been tested in several animal models of 
neurological diseases with promising results 
95, 96
. In an animal model of transient global 
forebrain ischaemia, KYNA exerted a neuroprotective effect by reducing the 
hippocampal CA1 pyramidal cell loss. The analogue was effective both as a pre-
treatment and as post-treatment 
96
. In a transgenic mice model of Huntington’s disease, 
the same analogue proved not only to ameliorate the motor symptoms but it also 
significantly, by more than 30%, prolonged the survival of the animals. The 
neuroprotective effect was also confirmed histologically: the KYNA analogue was able to 
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prevent neuronal atrophy in the striatum of the transgenic animals 
95
. As KYNA is an 
NMDA antagonist, an important concern would be the possible interference with the 
physiological glutamatergic functions. However, behavioral studies with this novel 
KYNA analogue confirmed, that in the same dose in which it proved to be 
neuroprotective, it did not induce any cognitive side effects
97
.   
 
 
Conclusion 
The therapeutic management of PD through dopamine replacement is associated with therapy-
related complications, which may have a more severe impact on the quality of life of patients 
than the parkinsonian motor symptoms. Alterations of the glutamatergic neurotransmission 
are implicated in the development of both LID and ICDs, and antiglutamatergic interventions 
may therefore be beneficial for these complications. KYNA as an NMDA antagonist 
compound, which is also able to influence dopaminergic neurotransmission may be a 
promising candidate for future drug development.  
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